Cronos Group Inc. delivered an organic record quarter in Q2 2026. Net revenue of $53.0M represents 58% year-over-year growth. The company also reported its tenth consecutive quarter of record net revenue in Israel. The PEACE NATURALS brand holds the leading medical cannabis position in that market. Adjusted EBITDA reached $13.1M in Q2 2026. Management frames the quarter as evidence that the company has translated its balance sheet strength into operating leverage. The shift from cash preservation to operating execution marks the most meaningful change in the operating profile since the Realignment initiative was launched. The Q2 result also produced record gross profit, with the margin expansion reflecting both volume leverage and geographic mix realignment toward excise-tax-free markets.
The Q2 2026 result reflects three reinforcing dynamics, with each contributing incremental gross profit through the same period. Israeli flower sales accelerated on the back of currency tailwinds, where the New Israeli Shekel strengthened against the U.S. dollar year over year. German and other international markets added a second leg of geographic diversification. The international bucket ex-Israel grew 88% on an organic basis. The Canadian adult-use market, where Spinach maintained the leading vape and edible share, contributed a third layer of growth. The three legs together produced the most balanced quarterly revenue mix in the company's history. Net revenue in Canada also reached a quarterly record, supported by vape and pre-roll category expansion that lifted Spinach to #2 overall national brand position.
Capital allocation discipline paired with the operational beat. The company repurchased 12.3M shares in the first half of 2026. Those repurchases totaled $32.9M of capital deployed under the program. Cash and short-term investments stood at $797.0M at quarter-end, providing what management characterized as ample optionality for the pending CanAdelaar acquisition and continued capital returns. The combination of growth, margin expansion, and balance sheet firepower positions Cronos as one of the more differentiated equity stories in the global cannabis FPI universe. The H2 2026 reporting cadence is set to determine whether the operating leverage sustains or represents a one-quarter spike. Cronos enters the second half of 2026 with the strongest combination of organic growth momentum and balance sheet flexibility in its public reporting history.